LUPIN - Lupin Ltd Share Price

In the Q3 FY2026 earnings call, management provided a positive outlook, emphasizing sustained growth across multiple regions driven by strong product performance. Key highlights include:

1. Revenue Growth: Total revenues reached INR 7,168 crores, a 24% Year-over-Year (YoY) increase, with the U.S. market contributing significantly with a remarkable 46% YoY growth, recording sales of USD 350 million.

2. Strong Product Performance: The U.S. growth was bolstered by new product launches such as Tolvaptan, and the successful approval of the biosimilar Pegfilgrastim, expected to launch before the end of the quarter. Management projected that the combined revenue from Pegfilgrastim, Ranibizumab, and Aflibercept could contribute around USD 100 million over the next few years.

3. Market Positioning in India: The Indian business grew 5.6% YoY, with a core prescription growth of 10.9%. Management expressed confidence in achieving double-digit growth, attributing this to a strong salesforce and a product pipeline poised to outperform the market significantly.

4. Emerging Markets: Emerging markets showed impressive growth at 42% YoY, particularly in Brazil, which grew 99% YoY, driven by the commercialization of Dapagliflozin.

5. R&D Investment: R&D spending remained robust at 7.5% of sales, reflecting a focus on complex products, with expectations that R&D investment will continue to drive long-term growth and innovation.

6. EBITDA Margins: EBITDA margins hit 31.1%, a 681 basis-point increase YoY, with full-year EBITDA margins anticipated between 27% to 28%.

7. Future Focus: Management reiterated plans to increase the share of complex products in the U.S. and expand the specialty portfolio through organic initiatives and targeted acquisitions, projecting a sustainable growth trajectory with strategic drivers in place.

Overall, management showcased an optimistic outlook driven by strong operational performance, strategic product launches, and robust pipeline development.

Question 1: "Could you highlight what will be the drivers of the US business once Tolvaptan and Mirabegron start tapering off?"
Answer: We're excited about our new product pipeline in the US. For instance, injectables like Glucagon and Liraglutide, alongside Pegfilgrastim which we recently approved, will contribute to future growth. We're targeting increased institutional sales, aiming to establish a strong biosimilars presence, projected to ramp up over the next three to five years. We also will introduce 505(b)(2) products, reinforcing our efforts to maintain revenue levels above $1 billion annually.

Question 2: "Can the combined basket of Pegfilgrastim, Ranibizumab, and Aflibercept contribute around USD 100 million in the next 2-3 years?"
Answer: Yes, we believe this potential is there. These biosimilars will become significant contributors, especially with Pegfilgrastim launching this quarter and Ranibizumab expected shortly thereafter. Our strategy is geared towards capturing a substantial market share early on, leveraging our integrated model to boost revenues efficiently.

Question 3: "Is there a timing prediction for the launch of Xywav?"
Answer: Yes, we anticipate being able to launch Xywav in FY29, assuming ongoing legal matters are resolved favorably. As we are the exclusive first to file, we expect to benefit significantly from that positioning.

Question 4: "What growth environment do you foresee for the India business, especially with recent IQVIA data indicating good momentum?"
Answer: We expect to outperform the market, targeting growth that is 20%-30% ahead of the industry. With the market growing robustly, double-digit expansion is likely over the next few years, supported by the upcoming Semaglutide launch and overall demand in chronic therapy areas.

Question 5: "Could you elaborate on your AI implementation across various divisions?"
Answer: We've made progress in incorporating AI across the organization, starting with sales and marketing. We're integrating AI into manufacturing, quality processes, and other functions. Our objective is to unify data repositories, enabling efficient pilot projects, with full implementations across the board expected in the next year.

Question 6: "What is the strategy for Semaglutide in terms of sales force?"
Answer: We have dedicated approximately 200 personnel focused on Semaglutide, with the flexibility to scale further based on demand. Our established presence in the cardio-metabolic market should help us capture significant market share promptly on launch.

Question 7: "Why only a USD 15 million provision for Mirabegron?"
Answer: The USD 15 million provision relates to past expenses, while the larger USD 75 million is tied to future payments as part of our market settlement. The latter will be amortized over time rather than impacting EBITDA directly in the immediate term.

Question 8: "Do you foresee improvements in the Mirabegron market share given this settlement?"
Answer: We currently hold a 40% share alongside competition from Zydus. With the settlement easing our litigation burdens, we aim to optimize our sales strategy to determine future share gains as product dynamics evolve.

Question 9: "What is the anticipated revenue from Semaglutide in its first year?"
Answer: Our internal forecasts suggest a potential market size of INR 1,500 crore for Semaglutide in its first year, with our target revenue being around INR 50-60 crores. However, the actual demand and pricing strategies will influence outcomes significantly in the early days.

Question 10: "How is the VISUfarma deal progressing?"
Answer: We anticipate closing the VISUfarma deal soon this quarter, with expectations of consolidating it in upcoming reports. We still project revenue contributions of approximately EUR 60 million from this acquisition moving forward.